Drugs / KNX100
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04901078 | Apr 2022 → Sep 2023 | opiate dependence | Kinoxis Therapeutics Pty Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KNX100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04901078 ↗ |
| Route | Oral | “KNX100 will be provided in capsule form as 5, 25 and 100 mg capsules for oral administration.” NCT04901078 ↗ |